Search

Your search keyword '"THILL, MARC"' showing total 611 results

Search Constraints

Start Over You searched for: Author "THILL, MARC" Remove constraint Author: "THILL, MARC"
611 results on '"THILL, MARC"'

Search Results

1. The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer

3. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

4. Spatial predictors of immunotherapy response in triple-negative breast cancer

5. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

7. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

10. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

11. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

14. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

15. Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie: 17. Internationale St.-Gallen-Konsensuskonferenz vor dem Hintergrund deutscher Therapieempfehlungen diskutiert

17. App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship - a multicentric randomized controlled trial.

18. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.

20. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

21. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

22. Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

23. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien

24. Supplementary Table 1 from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

25. Data from RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

26. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

27. Die CAPTOR-BC-Studie.

29. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung.

30. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial

32. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

33. An international comparative analysis and roadmap to sustainable biosimilar markets

36. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03

42. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

43. Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

44. Uncertainties and controversies in axillary management of patients with breast cancer

45. Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

47. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

49. Abstract P4-07-13: Satisfaction of patients after implant-based subpectoral reconstruction with a titanized polypropylene mesh (TiLOOP® Bra) compared to prepectoral reconstruction with a titanzied polypropylene pocket (TiLOOP® Bra Pocket)

50. Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer

Catalog

Books, media, physical & digital resources